ANDA 77982, held by Apotex. Alendronate Sodium.
As of Nov 16, 2026, ANDA 77982 (Alendronate Sodium), held by Apotex, was first approved by FDA on Aug 4, 2008, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 4, 2008 | Original application | Approved | None posted |
| Alendronate SodiumEQ 5MG BASE · tablet;oral | Alendronate Sodium | Discontinued |
| Alendronate SodiumEQ 10MG BASE · tablet;oral | Alendronate Sodium | Discontinued |
| Alendronate SodiumEQ 35MG BASE · tablet;oral | Alendronate Sodium | Discontinued |
| Alendronate SodiumEQ 70MG BASE · tablet;oral | Alendronate Sodium | Discontinued |
| May 7, 2026 | Supplement 13Labeling · Standard review | Approved | None posted |
| Mar 16, 2020 | Supplement 11Labeling · Standard review | Approved | None posted |
| Aug 26, 2016 | Supplement 9Labeling · Standard review | Approved | None posted |
| Aug 26, 2016 | Supplement 10Labeling · Standard review | Approved | None posted |
| Dec 23, 2014 | Supplement 2Labeling | Approved | None posted |
| Apr 24, 2014 | Supplement 7Labeling · Standard review | Approved | None posted |
| Apr 24, 2014 | Supplement 8Labeling · Standard review | Approved | None posted |
| Apr 30, 2012 | Supplement 4Labeling | Approved | None posted |
| Aug 4, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters